NCT00652730View on ClinicalTrials.gov

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 1998

Primary Completion Date

September 30, 1998

Study Completion Date

September 30, 1998

Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
DRUG

Buspirone HCl

Tablets, 30 mg, single-dose, fasting conditions

DRUG

Buspirone HCl

Tablets, 30 mg, single-dose, fed conditions

DRUG

Buspar

Tablets, 30 mg, single-dose, fed conditions

Trial Locations (1)

H4R 2N6

Phoenix International Life Sciences inc, Saint-Laurent

Sponsors
All Listed Sponsors
collaborator

Phoenix International Life Sciences, Inc.

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY

NCT00652730 - Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions | Biotech Hunter | Biotech Hunter